Cullinan Therapeutics, Inc.

In the quarter to June 2026, EPS grew 24.3% and free cash flow grew 33.7%, each against the same quarter a year earlier.

12.93 1.07 −7.64%

Follow CGEM

Alert me

	Jun '26	Mar '26	Dec '25	Sep '25	Older periods
ROE Full definition →	(50.30%)	(48.16%)	(44.02%)	(40.18%)	+8 more TTM periods Free account
ROA Full definition →	(46.30%)	(44.99%)	(41.09%)	(38.12%)
ROIC Full definition →	0.00%	(1,051.43%)	(489.82%)	(127.05%)
Return on Tangible Assets Full definition →	(67.87%)	(67.68%)	(62.92%)	(69.95%)
Free Cash Flow per Share Full definition →	(2.59)	(2.95)	(2.98)	(2.95)
Free Cash Flow Full definition →	(159.25)	(178.64)	(175.80)	(174.35)
Capital Expenditures Full definition →	—	—	(0.05)	(0.09)
Other line items
Cash ROIC Full definition →	(24.27%)	(24.88%)	(22.35%)	(22.24%)
Accounts Payable Turnover Full definition →	0.00	0.00	0.00	0.00
Average Days of Payables Full definition →	0.00	0.00	0.00	0.00
Tax Rate Full definition →	0.00	0.00	0.00	0.00
Research and Development Expense of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Selling, General and Administrative Expense of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Share Based Compensation of Revenue Full definition →	0.00%	0.00%	0.00%	0.00%
Operating CF/Net income Full definition →	0.78	0.81	0.80	0.80
Depreciation/Fixed assets Full definition →	1.20	0.92	0.74	0.63
Capex/Depreciation Full definition →	0.00	0.00	(0.16)	(0.28)
Revenue per Share Full definition →	0.00	0.00	0.00	0.00
Operating CF per Share Full definition →	(2.59)	(2.95)	(2.98)	(2.95)
Capex per Share Full definition →	0.00	0.00	0.00	0.00
Capex to Sales Full definition →	—	—	0.00	0.00

Columns are period end dates